Got a good line of products, but the share price seem to go down , could it be due to the weak us dollar.

Apr 16
Liberum Capital: Buy - TP: 5800p
Barclays..: Underweight - TP: 4770p
Credit Suisse: Neutral - TP: 4320p
Citigroup: Buy - TP: 5400p
Beaufort Securities: Hol

FDA grants another orphan drug designation

17 Apr; Deutsche Bank - Hold - TP up from 4800p to 4850p

Apr 17: Societe Generale: Buy - TP: 6600p

Apr 21: Barclays retains Underweight - TP up from 4770p to 4850p

AZN 1st quarter results

Apr 24:
Jefferies: Buy - TP: 5800p
Berenberg: Hold - TP: 4800p

Apr 29: Citigroup: Buy - TP: 5400p

May 21: Jefferies; Buy - TP: 5600p

May 26:
Barclays: Underweight. TP down from 4850p on 14 May to 4400p
Deutsche: Hold - TP: 4850p

AZN revenue ambitions hit by psoriasis drug setback

AZN news

June 1:
Deutsche Bank : Hold - TP: 4850p
Jefferies: Buy - TP: 5600p

June 2:
Jun Kepler Cheuvreeaux: Reduce - TP: 3700p
Exane BNP.: Outperform - TP: .5800p
JP Morgan: Neutral - TP: 4300p

Questor/Telegraph: Hold

JP Morgan: Neutral - TP up from 4300p to 4400p

June 26: HSBC new coverage: Hold - TP: 4640p

Questor/Telegraph: Buy

July 6: Jefferies: Buy - TP: 5600p

July 7: Oddo Securities - new coverage: Reduce - TP: 4400p

July 13: Jefferies Buy - TP down from 5600p to 5400p

FDA approves lung cancer treatment

StockMarketWire.com
AstraZeneca's core operating profits fell to $3,618m in the first half - 4% down 4% at constant exchange rates.

Total revenues were up 1% at constant rates at $12,364m and reported operating profits rose by 1% at constant rates to $1,856m.

The group said its robust top-line performance, supported by externalisation, underpins accelerated investment in R&D to progress pipeline, up 24% in H1.

Highlights:
· Core SG&A efficiency programme - early progress: Core SG&A 35% of Q2 Total Revenue (Q4 2014: 44%) - Sales & marketing effectiveness, centralisation of functions, process improvements, third-party spend, further efficiencies across support areas, footprint optimisation

· Core H1 EPS stable, up 3% in Q2, enhanced by one-off tax benefit

· FY 2015 Total Revenue guidance at CER improved: Now expected to decline by low single-digit percent (prior guidance - mid single-digit). Core EPS guidance at CER is unchanged: Expected to increase by low single-digit percent, reflecting the continued accelerated investment in R&D

· The Board recommends an unchanged first interim dividend of $0.90

Chief executive Pascal Soriot said: "We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas.

"I'm particularly pleased by the pace of progress in Oncology, with new approvals for both Iressa and Faslodex accompanied by regulatory submissions for AZD9291 and cediranib. The strong performance of the growth platforms and the subsequent upgrade to top-line guidance, together with increased R&D productivity reaffirm the confidence we have in our ability to navigate the final impacts from the loss of exclusivity and meet our revenue targets."